KOSDAQBiotech & Pharma086040

BiotoxtechCo

₩2,145▲ 2.39%2026-11-18 close
Market Cap
₩34.2B
Turnover
₩23,295,005
Volume
10K
Shares out.
16M
PER
—
PBR
1.0×
EPS
-₩667
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Order growth meets the test of sustained profit

Biotoxtech reported an operating profit in 3Q 2026 on overseas orders and subsidiary gains, but net losses attributable to controlling shareholders over the last four quarters total KRW 10.3 billion, so net profitability has not yet returned.

  1. 1

    Revenue rose 13.7% to KRW 47 billion in 2025, extending growth to a second straight year after the 2023 low. Operating loss narrowed to KRW 4.81 billion but remained a loss.

  2. 2

    Operating profit in 3Q 2026 was KRW 579 million, a swing to profit from the year-earlier loss, and revenue reached KRW 16.1 billion, up 35.0% year on year.

  3. 3

    Net loss attributable to controlling shareholders has continued for four consecutive quarters from 4Q 2025 through 3Q 2026, totaling KRW 10.3 billion, with the 3Q 2026 loss narrowing to KRW 797 million.

  4. 4

    The company reported a consolidated order backlog of KRW 60.7 billion at the end of 1H 2026 and said on September 30, 2026 that U.S. and European non-clinical orders are expected to roughly triple year on year in 2026.

  5. 5

    The debt-to-equity ratio stood at 312.2% at the end of 2025, with total liabilities of KRW 99.7 billion. Operating cash flow turned positive at KRW 6.64 billion in 2025.

02

Business structure

Biotoxtech is a non-clinical contract research organization that evaluates the efficacy and toxicity of drug candidates through animal studies.

Listed on KOSDAQ in 2007, it performs rodent and non-rodent toxicity assessments under GLP (Good Laboratory Practice) accreditation and also runs primate safety and efficacy testing. The company said it is also pursuing animal facility setup and consulting as well as early-stage drug candidate development.

The business splits into domestic and overseas non-clinical testing at the parent and non-human primate (NHP) testing at its primate-testing subsidiary. That subsidiary built NHP infrastructure in Osong, Chungbuk in 2022, and media reports put its 2025 revenue at KRW 14 billion, about 30% of consolidated sales.

Of 2024 consolidated revenue of KRW 41.3 billion, domestic sales were KRW 35.4 billion and exports KRW 5.9 billion, and the export share of total revenue rose to 16.8% in 2025.

Testing scope is shifting from small-molecule drugs toward advanced modalities such as ADCs, ASOs, peptides, next-generation vaccines and gene therapies.

Customers were historically concentrated in Japan but are broadening to the United States, Europe and Singapore, with about half of the subsidiary's total orders reported to come from U.S. and European clients.

The company says it competes on regulatory response capability and quality rather than price against multinational CROs, which are far larger. Celltrion holds an approximately 10.22% stake, and the largest shareholder group holds 23.83%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.9B-₩1.4B−11.5%
2025Q4₩14.2B-₩97,589,843−0.7%
2026Q1₩11.9B-₩1.8B−15.4%
2026Q2₩14.5B-₩200M−1.3%
2026Q3₩16.1B₩600M3.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩37.3B₩800M₩2.7B2.1%6.2%183.3%
2023₩32.6B-₩8.2B-₩4.9B−25.1%−9.4%204.8%
2024₩41.3B-₩8.9B-₩6.4B−21.5%−16.0%294.5%
2025₩47B-₩4.8B₩1.2B−10.2%2.9%312.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show a recovery from the 2023 trough. Revenue fell from KRW 37.3 billion in 2022 to KRW 32.6 billion in 2023, a 12.5% decline, then rose to KRW 41.3 billion in 2024 (up 26.7%) and KRW 47 billion in 2025 (up 13.7%).

Revenue grew in both 2024 and 2025, and 2025 was the largest year of the 2022 to 2025 period. Operating profit of KRW 800 million in 2022 turned into an operating loss of KRW 8.19 billion in 2023, widened to KRW 8.88 billion in 2024, and narrowed to KRW 4.81 billion in 2025.

The company attributed the 2025 improvement to fixed-cost absorption from higher revenue. Operating margin moved from 2.1% in 2022 to -25.1% in 2023, -21.5% in 2024 and -10.2% in 2025.

Net profit attributable to controlling shareholders turned positive at KRW 1.16 billion in 2025, while net loss including non-controlling interests was KRW 1.57 billion; the gap reflects non-controlling interests, and the company also said a fair-value gain on financial assets arose that year.

Total equity at the end of 2025 was KRW 31.9 billion, of which controlling shareholders' equity was KRW 40.2 billion, which implies negative non-controlling interests. Total liabilities were KRW 99.7 billion, and the debt-to-equity ratio climbed from 183.3% in 2022 to 312.2% in 2025.

Operating cash flow was negative in 2022 to 2024 and turned positive at KRW 6.64 billion in 2025.

Quarterly, the operating loss narrowed from KRW 1.36 billion in 3Q 2025 to KRW 97.59 million in 4Q 2025, widened to KRW 1.82 billion in 1Q 2026, then narrowed to KRW 182 million in 2Q 2026 before an operating profit of KRW 579 million in 3Q 2026.

Revenue hit its low of KRW 11.9 billion in 1Q 2026 and then rose to KRW 14.5 billion and KRW 16.1 billion in 2Q and 3Q 2026. Net loss attributable to controlling shareholders has run for four straight quarters since 4Q 2025, totaling KRW 10.3 billion, after a KRW 5.51 billion profit in 3Q 2025.

05

Industry analysis

Demand for non-clinical CRO services tracks early-stage drug development spending. In 2023, a downturn in Korea's biopharma sector and cuts to pipeline research budgets weighed on the industry, and the company's revenue fell to KRW 32.6 billion that year.

MT (Money Today) reported on March 31, 2026 that technology transfer deals by Korean pharma and biotech firms exceeded KRW 20 trillion for the first time in 2025, and analysts called this a favorable backdrop for non-clinical demand.

On policy, the formation of a Phase 3-focused fund and larger R&D budgets could feed into non-clinical and clinical testing demand. Media reports said the Ministry of Health and Welfare set aside KRW 2 billion for a 2027 program to develop globally competitive CROs.

Multinational CROs are far larger, and the company says it competes on regulatory response and quality rather than price. The company states it has completed on-site GLP inspections by the U.S. FDA, which it cites as a differentiator among domestic private non-clinical CROs.

Management also says primate testing demand exceeds supply and clients place advance orders, though this is the company's own characterization. Advanced modality testing such as ADC and ASO work is technically demanding and carries higher average order prices than standard tests.

Government budgets and technology transfer totals are industry-wide indicators and do not map directly onto the company's results.

06

Outlook

The outlook the company has laid out rests on order leading indicators and a rising overseas share. In a March 31, 2026 report, the company said it expects double-digit percentage revenue growth and better profitability in 2026.

For 1H 2026, standalone revenue rose 8% year on year to KRW 16.1 billion, new orders rose 17% to KRW 19.8 billion, and the standalone order backlog rose 18% to KRW 43.5 billion, according to the company. The consolidated backlog including its primate-testing subsidiary was KRW 60.7 billion.

On September 30, 2026, the company said it expects U.S. and European non-clinical orders in 2026 to roughly triple year on year, based on ADC, ASO and gene therapy work and follow-on package projects.

Media reports said 3Q 2026 contract count fell 30% year on year, while order value rose about 20% because of a larger share of high-margin long-term regulatory projects. The company also said facility and quality audits by U.S. and European biotech clients increased in 2H 2026, and audits typically precede awards.

The subsidiary began IPO procedures, according to a February 2026 report, but no listing schedule has been disclosed. The company says it will actively pursue shareholder returns including buybacks and cancellations.

The next checkpoint is how quickly the KRW 60.7 billion consolidated backlog converts into revenue from 4Q 2026 onward.

07

Valuation

PER
—
PBR
1.0×
ROE
-27.9%
EPS
-₩667
BPS
₩2,058
Dividend per share
₩0

Valuation is more directly read against net asset value than against earnings power, given the current facts. Net losses attributable to controlling shareholders over the last four quarters mean the price-to-earnings ratio is not meaningfully calculated.

The price-to-book ratio sits near net asset value, and the most direct comparison is market capitalization against controlling shareholders' equity of KRW 40.2 billion at the end of 2025.

Because total equity of KRW 31.9 billion sits below controlling shareholders' equity, non-controlling interests need to be considered alongside. Dividend yield is effectively nil.

The 2025 swing to net profit for controlling shareholders came partly with a fair-value gain outside operations, so the quality of the earnings recovery is better judged from quarterly operating results. The company disclosed buybacks of KRW 1 billion running from August 2025 through February 26, 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Shift toward overseas orders

The company forecast on September 30, 2026 that its 2026 U.S. and European non-clinical orders would roughly triple from the prior year. It says expanding into ADC, ASO and gene therapy testing could lift average order prices and margins. The consolidated backlog stood at KRW 60.7 billion at the end of 1H 2026.

Operating profit returned in 3Q 2026

Operating profit in 3Q 2026 was KRW 579 million, a swing from a year-earlier loss. Revenue reached KRW 16.1 billion, up 35.0% year on year, and has risen for two straight quarters from the 1Q 2026 low.

Media reports said the subsidiary posted its first quarterly operating profit since founding in 2Q 2026, on sales of KRW 5.8 billion.

Regulatory track record and shareholder base

The company says it has undergone on-site GLP inspection by the U.S. FDA. It reports that 25 non-clinical datasets it generated from 2023 through September 2026 were used in global regulatory approval processes, including 18 overseas IND filings and 7 NDA or BLA submissions. Celltrion's holding of roughly 10.22% is cited as a sign of technical credibility.

09

Bear factors

Losses persist at the net level

Net losses attributable to controlling shareholders total KRW 10.3 billion over the last four quarters, with losses in each quarter from 4Q 2025 through 3Q 2026. The operating loss widened to KRW 1.82 billion in 1Q 2026.

The company explained that 2025's net profit for controlling shareholders came in a year that also included a fair-value gain on financial assets, so it should be separated from operating earnings.

Balance sheet burden

Total liabilities at the end of 2025 were KRW 99.7 billion, and the debt-to-equity ratio rose from 183.3% in 2022 to 312.2% in 2025. Operating cash flow was negative from 2022 through 2024 and turned positive at KRW 6.64 billion in 2025. The company said facility investment and operating costs at the primate center widened the 2024 operating loss.

Industry cycle and order count volatility

In the 2023 downturn, revenue fell 12.5% and the company slid into operating losses, showing sensitivity to biopharma R&D cycles. The number of contracts in 3Q 2026 fell 30% year on year, a weakening on a count basis. The company said higher cost ratios from external uncertainty weighed on 1H 2026 operating results.

10

Risk factors

Lag between overseas orders and revenue

Projected U.S. and European order growth may translate into revenue later than expected, depending on client audits and contract timing. Non-clinical orders reportedly take several quarters to be recognized as revenue, creating a lag between backlog and quarterly results. Changes in overseas regulatory policy could also affect testing demand.

Fixed costs and capital structure

Primate testing facilities depend heavily on utilization to absorb fixed costs. In 2024, rising facility operating costs widened the operating loss. A 312.2% debt-to-equity ratio could translate into interest and working capital pressure.

Share price volatility and trading designation

On June 22, 2026, the stock was designated a one-day Investment Caution issue after a 7.32% one-day drop, with trading dominated by individual investors according to exchange data. Concentrated holdings by the largest shareholder group and Celltrion can amplify price swings when the free float is thin.

11

What to watch next

  1. Before March 31, 2027

    2026 annual report filing. It will confirm full-year operating results and how quickly the KRW 60.7 billion consolidated backlog converts into revenue. The company said profit would widen from 3Q 2026.

  2. By May 15, 2027

    1Q 2027 quarterly report. It will show whether operating results improve from the KRW 1.82 billion operating loss in 1Q 2026 and whether net losses attributable to controlling shareholders continue.

  3. Around March 2027

    Annual general meeting. It will show whether financial statements and shareholder-return items such as buybacks are on the agenda. The 2026 AGM was held on March 27, 2026.

  4. During 2027

    Execution of the Ministry of Health and Welfare's 2027 program to develop globally competitive CROs. It will show whether industry-wide demand for domestic CROs is affected.

12

Overall view

Biotoxtech grew revenue to KRW 47 billion in 2025 and disclosed an operating profit in 3Q 2026, but net losses attributable to controlling shareholders have continued for four consecutive quarters.

The 2025 swing to net profit for controlling shareholders coincided with a fair-value gain on financial assets, so the recovery in core operating earnings should be checked against later quarterly results.

Order indicators show clear strengths, including a KRW 60.7 billion consolidated backlog at the end of 1H 2026 and a projected roughly threefold rise in U.S. and European non-clinical orders.

Weaknesses include a 312.2% debt-to-equity ratio, KRW 99.7 billion in total liabilities at the end of 2025, and KRW 10.3 billion in net losses attributable to controlling shareholders over the last four quarters.

The industry backdrop includes supportive signals such as government R&D budgets and rising technology transfer activity, but in 2023 revenue fell when R&D spending was cut.

The price-to-earnings ratio is not meaningfully calculated and dividends are effectively nil, so net asset value and the pace of order recovery are the key reference points. The next checkpoint is the 2026 annual report, covering full-year operating results and how quickly overseas orders convert into revenue. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. news.bizwatch.co.kr
  3. comp.wisereport.co.kr
  4. thevc.kr
  5. mt.co.kr
  6. fnnews.com
  7. biz.heraldcorp.com
  8. catch.co.kr
  9. news.nate.com
  10. supple.kr
  11. vegannews.co.kr
  12. wowtv.co.kr
  13. m.news.nate.com
  14. mt.co.kr
  15. view.asiae.co.kr
  16. topstarnews.net
  17. view.asiae.co.kr
  18. topstarnews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis